SCHEMBL3547710

SCHEMBL3547710

COc1cc(C(=O)SC)cc(C(F)(F)F)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
LMNA P02545 6/20 0.49
ALDH1A1 P00352 4/20 0.49
HTT P42858 3/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 1/20 0.45
CYP3A4 P08684 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TPMT P51580 1/20 0.41
CYP2C9 P11712 2/20 0.40
TUBB1 Q9H4B7 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553862 0.81 LMNA (0.47) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL3549370 0.80 ALDH1A1 (0.46) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL3544899 0.79 PPARA (0.39) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL3553864 0.76 ALDH1A1 (0.42) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL3547712 0.75 MAPT (0.44) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL3548210 0.75 MAPT (0.44) MAPTLMNAALDH1A1HTTKMT2A
SCHEMBL896271 0.71 ALDH1A1 (0.46) MAPTLMNAALDH1A1HTTGAA
SCHEMBL14601582 0.71 ABCG2 (0.45) MAPTLMNAALDH1A1KMT2AGAA
SCHEMBL16610368 0.71 KDM4E (0.72) ALDH1A1HTTGAACYP3A4CYP2C19
SCHEMBL10322710 0.70 TPMT (0.41) MAPTLMNAHTTGAATPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE MAPT 3703/4885LMNA 3400/4885ALDH1A1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.